Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Blood

• Publication date

  2017-08-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2016-09-741983PMID 28646117
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma

  2016cited by this paper
• Overview of CDK9 as a target in cancer research

  2016cited by this paper
• Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.

  2016cited by this paper
• Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.

  2015cited by this paper
• The history and future of targeting cyclin-dependent kinases in cancer therapy

  2015cited by this paper
• Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study

  2015cited by this paper
• Antitumor effects of bevacizumab in a microenvironment‐dependent human adult T‐cell leukemia/lymphoma mouse model

  2014cited by this paper
• Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.

  2014cited by this paper
• Phase I Trial of Bortezomib (PS-341; NSC 681239) and “Nonhybrid” (Bolus) Infusion Schedule of Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-cell Neoplasms

  2014cited by this paper
• Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors

  2014cited by this paper
• HTLV-1 bZIP Factor–Specific CD4 T Cell Responses in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation

  2014cited by this paper
• Dysregulation of the basal RNA polymerase transcription apparatus in cancer

  2013cited by this paper
• A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

  2013cited by this paper
• Tax is a potential molecular target for immunotherapy of adult T‐cell leukemia/lymphoma

  2012cited by this paper
• Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma.

  2012cited by this paper
• Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study.

  2012cited by this paper
• The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

  2012cited by this paper
• Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

  2012cited by this paper
• Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.

  2011cited by this paper
• Antibody therapy for Adult T-cell leukemia–lymphoma

  2011cited by this paper
• Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.

  2010cited by this paper
• Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.

  2010cited by this paper
• Bortezomib‐induced apoptosis in mature T‐cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl‐1

  2009cited by this paper
• Abrogation of signal-dependent activation of the cdk9/cyclin T2a complex in human RD rhabdomyosarcoma cells

  2007cited by this paper
• Modulation of the Brd4/P-TEFb Interaction by the Human T-Lymphotropic Virus Type 1 Tax Protein

  2007cited by this paper
• Tax Interacts with P-TEFb in a Novel Manner To Stimulate Human T-Lymphotropic Virus Type 1 Transcription

  2006cited by this paper
• A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

  2006cited by this paper
• Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors

  2005cited by this paper
• Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.

  2005cited by this paper
• CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation

  2004cited by this paper
• The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma

  2004cited by this paper
• Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma

  2004cited by this paper
• Identification of differentially expressed molecules in adult T‐cell leukemia cells proliferating in vivo

  2004cited by this paper
• Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome.

  2003cited by this paper
• Androgen Receptor Interacts with the Positive Elongation Factor P-TEFb and Enhances the Efficiency of Transcriptional Elongation*

  2001cited by this paper
• Serial Transplantation of Adult T Cell Leukemia Cells into Severe Combined Immunodeficient Mice

  1996cited by this paper
• Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma

  1991cited by this paper
• Monoclonal antibody defining tax protein of human T-cell leukemia virus type-I.

  1989cited by this paper
• Serum Soluble Interleukin‐2 Receptor Levels in Patients with Adult T‐cell Leukemia and Human T‐cell Leukemia/Lymphoma Virus Type‐I Seropositive Healthy Carriers

  1988cited by this paper
• Isolation and transmission of human retrovirus (human t-cell leukemia virus).

  1983cited by this paper
• Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.

  1982cited by this paper
• Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.

  1981cited by this paper
• Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma

  1980cited by this paper
• Adult T-cell leukemia: clinical and hematologic features of 16 cases.

  1977cited by this paper

• Dinaciclib reduces MCL-1 levels and triggers apoptosis in adult T-cell leukemia/lymphoma.

  2026cites this paper
• Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer

  2025cites this paper
• Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects.

  2025cites this paper
• Targeting CDK9-dependent transcriptional addiction: a novel chemoprevention strategy for oral carcinogenesis via adenosine deaminase modulation

  2025cites this paper
• FeaSion decodes the regulatory landscape and functional diversity of RNA polymerase II CTD phosphorylation

  2025cites this paper
• CDK9 recruits HUWE1 to degrade RARα and offers therapeutic opportunities for cutaneous T-cell lymphoma

  2024cites this paper
• Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer.

  2024cites this paper
• Identification of Potent CDK9 Inhibitors with Novel Skeletons via Virtual Screening, Biological Evaluation, and Molecular Dynamics Simulation

  2024cites this paper
• New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches

  2023cites this paper
• The Application of pyrrolo[2, 3-d]pyrimidine scaffold in medicinal chemistry from 2017 to 2021.

  2023cites this paper
• Discovery of novel and bioavailable histone deacetylases and cyclin-dependent kinases dual inhibitor to impair the stemness of leukemia cells.

  2023cites this paper
• Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

  2023cites this paper
• CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma.

  2023cites this paper
• 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) induces apoptosis in breast cancer cells through inhibiting of Mcl-1 expression

  2023cites this paper
• VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

  2022cites this paper
• Alvocidib inhibits IRF4 expression via super‐enhancer suppression and adult T‐cell leukemia/lymphoma cell growth

  2022cites this paper
• Synthesis and Biological Evaluation of Imadazo[1,2-a]pyrazines as Anticancer and Antiviral Agents through Inhibition of CDK9 and Human Coronavirus

  2022cites this paper
• Molecular insights on selective and specific inhibitors of Cyclin Dependent Kinase 9 enzyme (CDK9) for the purpose of cancer therapy.

  2022cites this paper
• Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer

  2022cites this paper
• CDK9 inhibitors in cancer research.

  2022cites this paper
• Transcriptional regulators of human oncoviruses: structural and functional implications for anticancer therapy

  2022cites this paper
• First-in-human dose escalation study of cyclin-dependent kinase-9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy.

  2022cites this paper
• Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy

  2021cites this paper
• The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death

  2021cites this paper
• The Expression and Roles of the Super Elongation Complex in Mouse Cochlear Lgr5+ Progenitor Cells

  2021cites this paper
• Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• Targeting cyclin-dependent kinase 9 in cancer therapy

  2021cites this paper
• Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.

  2020cites this paper
• Expression and clinical value of PD‐L1 which is regulated by BRD4 in tongue squamous cell carcinoma

  2020cites this paper
• Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067

  2020cites this paper
• Super elongation complex as a targetable dependency in diffuse midline glioma

  2020cites this paper
• CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.

  2020cites this paper
• Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside.

  2020cites this paper
• Discovery of coumarin derivatives as potent and selective cyclin-dependent kinase 9 (CDK9) inhibitors with high antitumour activity.

  2020cites this paper
• Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors.

  2020cites this paper
• Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.

  2020cites this paper
• Cyclin-Dependent Kinase 9 (CDK9) Inhibitor Atuveciclib Suppresses Intervertebral Disk Degeneration via the Inhibition of the NF-κB Signaling Pathway

  2020cites this paper
• Non-cytotoxic 1,2,3-triazole tethered fused heterocyclic ring derivatives display Tax protein inhibition and impair HTLV-1 infected cells.

  2020cites this paper
• Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway

  2020cites this paper
• Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.

  2020cites this paper
• Molecular Pathology of HTLV-1

  2019cites this paper
• Clinical Approaches of HIV-1/HTLV-1 Co-infection Still Keep their Mysteries

  2019cites this paper
• A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

  2019cites this paper
• Cyclin-dependent kinase 9 expression and its association with CD8+ T cell infiltration in microsatellite-stable colorectal cancer

  2019cites this paper
• AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells

  2019cites this paper
• Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma

  2019cites this paper
• Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer.

  2019cites this paper
• Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma

  2019cites this paper
• Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer

  2019cites this paper
• Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.

  2019cites this paper
• Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia

  2019cites this paper
• 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.

  2019cites this paper
• Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphoma

  2018influential citation
• Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia

  2018cites this paper
• Is cyclin-dependent kinase 9 a novel specific molecular target of adult T-cell leukemia/lymphoma?

  2018cites this paper
• Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia

  2018cites this paper
• Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma

  2018cites this paper
• Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma

  2018cites this paper
• Epidemiology of malignant lymphoma and recent progress in research on adult T-cell leukemia/lymphoma in Japan

  2018cites this paper
• CDK9 inhibitors in acute myeloid leukemia

  2018cites this paper
• Protein partners of the eEF 1 Bβ subunit of the translation elongation complex eEF 1 B in the nuclear fraction of human lung carcinoma cells

  2017cites this paper
• Protein partners of the eEF1Bβ subunit of the translation elongation complex eEF1B in the nuclear fraction of human lung carcinoma cells

  2017cites this paper
• HTLV-1, the Other Pathogenic Yet Neglected Human Retrovirus: From Transmission to Therapeutic Treatment

  2017cites this paper
• CDK9 inhibition for ATL therapy.

  2017cites this paper
• Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia

  2017cites this paper